| 000 | 01646 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518054513.0 | ||
| 264 | 0 | _c20200409 | |
| 008 | 202004s 0 0 eng d | ||
| 022 | _a1744-8301 | ||
| 024 | 7 |
_a10.2217/fon-2019-0370 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBardia, Aditya | |
| 245 | 0 | 0 |
_aEMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. _h[electronic resource] |
| 260 |
_bFuture oncology (London, England) _cOct 2019 |
||
| 300 |
_a3209-3218 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial Protocol; Journal Article | ||
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aEstrogen Receptor alpha _xmetabolism |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aFulvestrant _xadministration & dosage |
| 650 | 0 | 4 | _aInternational Agencies |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTetrahydronaphthalenes _xadministration & dosage |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aMulticenter Studies as Topic |
| 700 | 1 | _aAftimos, Philippe | |
| 700 | 1 | _aBihani, Teeru | |
| 700 | 1 | _aAnderson-Villaluz, Alfred T | |
| 700 | 1 | _aJung, JungAh | |
| 700 | 1 | _aConlan, Maureen G | |
| 700 | 1 | _aKaklamani, Virginia G | |
| 773 | 0 |
_tFuture oncology (London, England) _gvol. 15 _gno. 28 _gp. 3209-3218 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/fon-2019-0370 _zAvailable from publisher's website |
| 999 |
_c30019218 _d30019218 |
||